GDXJ vs IBB
VanEck Junior Gold Miners ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.52% for GDXJ.
- • GDXJ pays a higher dividend yield (2.70%).
Side-by-side metrics
| Metric | GDXJ | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.52% | 0.44% |
Dividend yield Trailing 12-month yield. | 2.70% | 0.22% |
AUM Assets under management — bigger funds are typically more liquid. | $7.08B | $9.09B |
YTD return | -15.98% | 16.44% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.96 | 0.69 |
P/E ratio | 13.44 | 24.79 |
Last price | $99.52 | $196.62 |
Inception | — | — |
Issuer | VanEck | iShares |
GDXJ top holdings
| EVN.AX | Evolution Mining Ltd | 6.49% |
| AGI.TO | Alamos Gold Inc Class A | 6.26% |
| EQX.TO | Equinox Gold Corp Ordinary Shares Class A | 6.24% |
| EDV.L | Endeavour Mining PLC | 5.34% |
| CDE | Coeur Mining Inc | 5.10% |
| PE&OLES.MX | Industrias Penoles SAB de CV | 2.91% |
| AG.TO | First Majestic Silver Corp | 2.67% |
| IMG.TO | Iamgold Corp | 2.61% |
| HL | Hecla Mining Co | 2.60% |
| ELD.TO | Eldorado Gold Corp | 2.47% |
IBB top holdings
| VRTX | Vertex Pharmaceuticals Inc | 8.07% |
| AMGN | Amgen Inc | 7.82% |
| GILD | Gilead Sciences Inc | 6.83% |
| REGN | Regeneron Pharmaceuticals Inc | 4.90% |
| ARGX | argenx SE ADR | 3.75% |
| ALNY | Alnylam Pharmaceuticals Inc | 3.12% |
| NTRA | Natera Inc | 2.89% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.78% |
| BIIB | Biogen Inc | 2.46% |
| ILMN | Illumina Inc | 2.07% |
About GDXJ
GDXJ (VanEck Junior Gold Miners ETF) is Small and mid-cap gold and silver mining companies. Managed by VanEck, the fund carries $7.1B in assets under management, an expense ratio of 0.52%, a dividend yield of 2.70%. Its largest holding is Evolution Mining Ltd (EVN.AX), which represents 6.5% of the portfolio. Basic Materials is the fund's largest sector exposure at 100.0%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $9.1B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.22%. Its largest holding is Vertex Pharmaceuticals Inc (VRTX), which represents 8.1% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.